Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases

Susan Bernstein  |  February 16, 2016

SAN FRANCISCO—Metabolomics could one day be a treasure map of information about inflammation in rheumatic disease. There are many metabolic pathways to pursue for clues on how to reverse this damaging process. “All of these signaling pathways are interrelated and affect each other,” said Douglas J. Veale, MD, director of translational research at Dublin Academic…

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)inflammationinflammatorymetabolicpathwaysResearchRheumatic Diseaserheumatologysignaling

Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

Michele B. Kaufman, PharmD, BCGP  |  February 16, 2016

Biosimilars Receive Positive News On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 If approved, Benepali can be used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis and plaque psoriasis….

Filed under:Biologics/DMARDsDrug Updates Tagged with:ApprovalsBiosimilarsdrugFDAIbuprofenMethotrexatepregabalinRheumatoid arthritisrheumatologySafetysarilumab

FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Reuters Staff  |  February 6, 2016

(Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product. The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc.,…

Filed under:Axial SpondyloarthritisBiologics/DMARDsDrug Updates Tagged with:Ankylosing SpondylitisCelltrion Inc.FDAFood and Drug Administrationinfliximabmonoclonal antibodyRemsimaRheumatoid Arthritis (RA)

The Genetic Factor: Research Examines Genetic Heritability for Pediatric Autoimmune Diseases

Richard Quinn  |  February 5, 2016

Recent research has helped further define genetic heritability for pediatric autoimmune diseases. In an interview, Dr. Hakon Hakanarson discusses how understanding common genetic factors can help develop risk prediction and treatments for such diseases as juvenile idiopathic arthritis, lupus and celiac disease…

Filed under:Conditions Tagged with:Autoimmune diseaseGenetic researchgenetic riskgenomicsPediatric RheumatologyPediatrics

Apremilast Effective for Psoriatic Arthritis

Reuters Staff  |  February 2, 2016

NEW YORK (Reuters Health)—Apremilast improves clinical outcomes in patients with psoriatic arthritis and active psoriasis, according to results from the PALACE 3 randomized controlled trial. Apremilast, a phosphodiesterase 4 (PDE4) inhibitor, showed efficacy against psoriatic arthritis in the PALACE 1 trial. Dr. Christopher J. Edwards from University Hospital Southampton in the U.K. and colleagues evaluated…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:apremilastPsoriasisPsoriatic Arthritis

Secukinumab Receives 2 New Approvals: PsA & AS

Michele B. Kaufman, PharmD, BCGP  |  January 20, 2016

The FDA approved secukinumab (Cosentyx) this past week for the treatment of adults with active ankylosing spondylitis and active psoriatic arthritis. These two new approvals are based on the safety and efficacy outcomes from four placebo-controlled Phase 3 trials in more than 1,500 adults with AS or PsA…

Filed under:Biologics/DMARDsDrug Updates

FDA Approves New Drugs for Pain

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2016

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsFDAOsteoarthritisPainrheumatologySafety

Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.

Michele B. Kaufman, PharmD, BCGP  |  January 6, 2016

In Europe, an etanercept biosimilar is getting closer to being approved to treat RA and more, and in the U.S., an application for an adalimumab biosimilar has been submitted for FDA approval. Also, an analysis of methotrexate use in the U.S. shows that therapy may actually be underused for RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:axial spondyloarthritis (SpA)BiosimilarsEuropean Medicines AgencyMethotrexateplaque psoriasisPsoriatic ArthritisRheumatoid Arthritis (RA)

Case Report: Sternoclavicular Erosions in a Patient with Uncontrolled RA

Diana M. Girnita, MD, PhD, Avis Ware, MD, Sangita Kapur, MD, & Christine Chhakchhuak, MD  |  December 17, 2015

Sternoclavicular joint involvement has rarely been reported in the context of active rheumatoid arthritis (RA).1 Traditionally, rheumatologists use serial radiographs of hands and feet to diagnose, monitor for progression or evaluate the response to treatment. The sternoclavicular (SC) joint is not a typical joint assessed for RA. However, the fact that it is a diarthrodial…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ClinicalDiagnosisoutcomepatient careRARheumatoid arthritisSCsternoclavicular jointTreatment

New SLE Drug May Allow Patients to Reduce Steroid Use

Michele B. Kaufman, PharmD, BCGP  |  December 16, 2015

In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:anifrolumabAnkylosing SpondylitisEuropePsoriatic Arthritissecukinumabsystemic lupus erythematosus (SLE)

  • « Previous Page
  • 1
  • …
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences